Market Research Logo

Pancreatic Endocrine Tumor - Pipeline Review, H2 2015

Pancreatic Endocrine Tumor - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pancreatic Endocrine Tumor - Pipeline Review, H2 2015’, provides an overview of the Pancreatic Endocrine Tumor’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Endocrine Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Endocrine Tumor
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatic Endocrine Tumor and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatic Endocrine Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatic Endocrine Tumor pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Endocrine Tumor
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatic Endocrine Tumor pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pancreatic Endocrine Tumor Overview
Therapeutics Development
Pipeline Products for Pancreatic Endocrine Tumor - Overview
Pipeline Products for Pancreatic Endocrine Tumor - Comparative Analysis
Pancreatic Endocrine Tumor - Therapeutics under Development by Companies
Pancreatic Endocrine Tumor - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pancreatic Endocrine Tumor - Products under Development by Companies
Pancreatic Endocrine Tumor - Companies Involved in Therapeutics Development
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
MediaPharma s.r.l.
Novartis AG
Tyrogenex, Inc.
Pancreatic Endocrine Tumor - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
lanreotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MPHE-001B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pasireotide LAR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHR-1020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
X-82 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pancreatic Endocrine Tumor - Recent Pipeline Updates
Pancreatic Endocrine Tumor - Discontinued Products
Pancreatic Endocrine Tumor - Product Development Milestones
Featured News & Press Releases
Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium
Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumours
May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Apr 14, 2015: MHRA approves Ipsen’s Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumours
Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium
Dec 16, 2014: Ipsen’s Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pancreatic Endocrine Tumor, H2 2015
Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Pancreatic Endocrine Tumor - Pipeline by Ipsen S.A., H2 2015
Pancreatic Endocrine Tumor - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Pancreatic Endocrine Tumor - Pipeline by MediaPharma s.r.l., H2 2015
Pancreatic Endocrine Tumor - Pipeline by Novartis AG, H2 2015
Pancreatic Endocrine Tumor - Pipeline by Tyrogenex, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pancreatic Endocrine Tumor Therapeutics - Recent Pipeline Updates, H2 2015
Pancreatic Endocrine Tumor - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pancreatic Endocrine Tumor, H2 2015
Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report